|
|
|
|
|
|
|
Mon T W Th F |
|
1 June, 2026 |
|
|
|
|
|
|
|
|
|
|
|
|
Servier pulled off one of the largest upfront asset deals of 2026 by shelling out $1.55 billion for Edgewise Therapeutics' muscular dystrophy treatments, surpassing the $1.2 billion upfront that AstraZeneca paid in an obesity pact with CSPC Pharmaceutical in January. The banner year continues for Servier after it purchased Day One Biopharmaceuticals. Get the details from Kyle LaHucik here, and there's more to come from ASCO! |
|
|
|
Alex Hoffman |
Senior Copy Editor, Endpoints News
|
|
|
|
|
|
|
by Kyle LaHucik
|
Servier will pick up the muscular dystrophy business from Edgewise Therapeutics for $1.55 billion upfront, giving the French pharma company access to an experimental neuromuscular... | |
|
|
|
 |
|
Athena Countouriotis, Avenzo Therapeutics CEO (via BioMarin) |
|
|
|
by Kyle LaHucik
|
Avenzo Therapeutics, one of the first biotechs to get major Western VC backing to in-license Chinese assets, will go public in a reverse merger with... | |
|
|
|
|
|
|
|
|
by Max Gelman
|
CHICAGO — AstraZeneca on Monday reported data from a new study showing the combination of a targeted treatment and two immunotherapies can benefit patients with... | |
|
|
|
 |
|
Inside #ASCO26 (Karen Weintraub for Endpoints News) |
|
|
|
by Lei Lei Wu
|
CHICAGO —Eli Lilly in April penned an up to $7 billion deal to buy Kelonia Therapeutics, and now we know why. All 18 multiple... | |
|
|
|
|
|
